Net exposure 500 varieties will be collected! 3 years to complete a number of heavy biological drugs, insulin selected.

In recent days, the industry has frequently flowed out of the relevant departments on Friday (July 24) to carry out the main points of the national collection meeting.
network content related to the future of the national collection coverage of varieties, as well as provincial collection of key tasks, as well as the third batch of national collection of the latest news.
The specific points are as follows: 01 3 years to complete 500 varieties of collection network content pointed out that the future volume of procurement will be full coverage at the national, provincial and municipal levels;
content revealed that the National Health Insurance Administration requires according to the purchase amount of order, covering the first 80% of the drug about 500, each place can be determined according to the specific situation of the number, specifically in 2021 to cover 250, 2022 to be fully covered.
not carried out in the country, it will be organized by the provinces.
range of products, clinical sales, generic drugs more than three.
This means that the volume of procurement will be all over the country flowering, and by the local collection of varieties, it is very likely to be included in the national collection, even if temporarily not included, once the national linkage of the lowest price, for enterprises is also a big shock, clinical use of large, high proportion of varieties in the future will be "one can not be less" into the collection catalog.
Previous documents mentioned that the pilot provinces of comprehensive medical reform should take the lead in carrying out volume procurement of drugs not included in the national collection by the end of September, and this document directly requires all provinces to carry out this year, the second half of the provincial collection is expected to be one of the important points of view.
500 species to be collected within 3 years refer to from Insight database 02 wolves come! Biopharmaceasing, insulin selection is worth noting, within 3 years will be collected in the list of 500 varieties, varieties covered with biological drugs, insulin.
of which biological drugs are beneficial to the toxi monoantigen, quercetumad monoanti, are Roche's heavy tumor drugs.
there are many domestic enterprises layout of these two drugs bio-similar drug pipeline.
February 2019, Fuhong Hanlitoxi single anti-injection was approved for market, becoming the first domestic biosychic drug.
In the research and development competition of lysoxi single anti-similar drugs, in addition to Fuhong Hanxuan, there are Cyntaf Biology, Shenzhou Cell Engineering;
According to media statistics, there are more than 10 domestic pharmaceutical companies are developing qutoju single resistance, there are 7 pharmaceutical companies into Phase III clinical, involving Zhengda Tianqing, Hualan gene, Haizheng Pharmaceuticals, Jiahe biology, anthropology and so on.
the list also includes several insulin varieties, such as sperm protein biosynthetic human insulin (30R) injection form, sperm protein biosynthetic human insulin (50R) injection form, mendon insulin injection form, tetratin insulin injection form, recombinant Insulin glycerin injection type, refined protein zinc recombinant human insulin (70/30) injection, refined protein zinc recombinant insulin (25R) injection type, refined protein zinc recombinant insulin (50R) injection type.
, refined protein biosynthetic human insulin belongs to the second generation of insulin products.
, teter insulin, recombinant insulin glycelin, etc. belong to the third generation of insulin products.
of key urban sample hospital data show that the current insulin market in China is mainly occupied by the third generation of insulin, accounting for more than 80% of the total, the rest by the second generation of insulin occupied.
Overall, the insulin market is mainly occupied by No. Nord, Sanofi, Lilly, market share of more than 80%, the third generation of insulin only insulin glycelin localization slightly higher, but only 25%.
with the domestic three generations of insulin has been approved for listing, as well as with the volume of procurement, the process of domestic replacement is expected to accelerate.
the above-mentioned varieties involved in the main domestic production enterprises are Gan Li Pharmaceuticals, Tonghua Dongbao, Federal Pharmaceuticals and so on.
with the catalog, which means that biologics and insulin are collected not just for a gust of time, the wolf is really coming.
addition, the catalog also has 14 varieties in last year's first national focus on monitoring rational drug use.
are mainly neurostatin sodium injection type, oral and injection type of oxytoxitan, prostatil injection type, curcumin hydrolyte injection type, compound coenzyme injection type, dansankawaxin injection, conversion of glycogen The injection type of electrolyte, the injection type of thymus quinte, the injection type of Ida lafon, the injection type of bone peptide, the injection type of cerebroprotein hydrolyte, the injection type of ribonucleic acid, the injection type of Changchun citin, the injection type of calf blood deprotein extract injection type.
also pointed out that the provinces do not worry about the flow of labels, the flow of products reported to the National Health Insurance Administration in a timely manner, will further study the reasons.
refers to the above-mentioned varieties, the back will appear in which provincial harvest.
With the development of volume procurement, China's generic drug enterprises profits are constantly compressed, the future needs pharmaceutical companies in the control of costs at the same time to ensure sales, with the integration of raw materials pharmaceutical production lines in the bargaining environment advantages highlighted.
with the variety of coverage more and more, the old pharmaceutical market pattern will be broken, the entire industry accelerated shuffle.
03 The third batch of national mining rules at the end of this month, the content of the online message said that the third batch of national mining rules are basically finalized, is expected to open on August 18, the end of July issued implementation plans and rules, the rules will use the second batch of national rules, such as 1.8 times the fuse mechanism and price reduction of 50%.
, the highest effective declared price for purchases and products has been issued, and the mechanism for retaining the balance of the health insurance fund will be increased.
Sina Pharmaceuticals inquired about the second batch of national collection announcement, the rules show that: the proposed selection of enterprises to determine the criteria for the finalists of the enterprise price meets one of the following conditions, to obtain the proposed selection qualification: 1." 1.8 times the unit comparable price of "the lowest unit equivalent price of the same variety"; Unit declared price "decrease of 50.00%;3." The unit can be compared to the price of "0.1000 yuan."
is not surprising that the third and second instalments are separated by half a year.
And, from the 4-7 pilot to the third batch, with the volume of procurement varieties continue to expand, the rules are constantly improving, drug belt procurement has been repeatedly written into the key tasks of medical reform, it is expected that the belt procurement mechanism will only be constantly improved.
In addition, the outflow of the content also mentioned to increase the balance of the health insurance fund retention mechanism, after similar rules exposed such as the requirement is "such as the number of 1 million tablets, requiring the completion of 60%, if the hospital completed more than 600,000 tablets, not more than 1 million tablets, savings part of the award hospital half, more than 1 million pieces of cancellation incentives;
" Last year, in the pilot of the 4-7 urban belt procurement, Dalian in the establishment of the implementation rules of collection, one of them is to improve the balance retention mechanism, "medical institutions because of the standardized use of selected varieties and complete the amount of the reduction of medical insurance fund expenditure, medical institutions can be retained, and in accordance with the relevant provisions can be used to coordinate the remuneration expenditure for medical personnel, in order to mobilize the enthusiasm of medical personnel."
" Third batch of countries if the increase in the health insurance fund balance retention mechanism, I do not know whether it will refer to the practice of pilot cities.
we will continue to pay attention.
.